Newsletter Tool

Today’s Big News

Mar 19, 2024

AstraZeneca melds with Fusion in $2B radiopharma buyout

Bayer ready to take rival to Astellas' Veozah to regulators after phase 3 hat trick

The obesity pipeline was 'late breaking.' Here's what the R&D landscape looks like now

Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry

Tenaya gene therapy for deadly heart condition boosts long-term survival in mice

Innovent’s anti-VEGF drug matches Eylea in phase 2 eye disease trial

Seelos’ IV-administered sugar therapy fails to improve ALS severity in midstage trial

Eliem cuts in on Tango, proposes acquisition after strategic review

Featured

AstraZeneca melds with Fusion in $2B radiopharma buyout

By Nick Paul Taylor

AstraZeneca is adding to the explosion of interest in radiopharmaceuticals, inking a $2 billion buyout to meld Fusion Pharmaceuticals with its cancer unit.

Bayer ready to take rival to Astellas' Veozah to regulators after phase 3 hat trick

By James Waldron

Bayer's hot flash drug elinzanetant has struck phase 3 gold again by relieving vasomotor symptoms, setting up the pharma to approach regulators about following Astellas’ Veozah to market.

The obesity pipeline was 'late breaking.' Here's what the R&D landscape looks like now

By Annalee Armstrong,Gabrielle Masson

If you’re feeling like the obesity pipeline filled up overnight, you’re not alone. A new analysis from IQVIA takes a look at the drugs in development.

Engrail closes $157M series B, fueled by investors' renewed interest in neuropsychiatry

By Max Bayer

Neuropsychiatry biotech Engrail has closed a $157 million series B, adding crucial capital to help pay for clinical trials. The round was co-led by F-Prime Capital, Forbion and Norwest Venture Partners.

Tenaya gene therapy for deadly heart condition boosts long-term survival in mice

By Helen Floersh

Tenaya Therapeutics’ gene therapy for an inherited heart condition that can cause sudden death appears to be effective in mice, new data show.

Innovent's anti-VEGF drug matches Eylea in phase 2 eye disease trial

By James Waldron

Innovent’s anti-VEGF drug held its own against Regeneron and Bayer’s blockbuster eye disease therapy Eylea in a phase 2 trial.

Seelos’ IV-administered sugar therapy fails to improve ALS severity in midstage trial

By Max Bayer

Seelos Therapeutics midstage ALS med failed to improve disease severity in a phase 2/3 trial. But the company contends the data are more promising in patients who didn't receive Amylyx's Relyvrio during the study.

Eliem cuts in on Tango, proposing acquisition after strategic review

By Gabrielle Masson

Eliem Therapeutics is sashaying away from the brink of closure, joining hands with Tango Therapeutics after reviewing strategic alternatives.

After Kyowa Kirin buyout, Orchard scores FDA approval for first MLD gene therapy in the US

By Fraiser Kansteiner

The FDA on Monday gave a thumbs up to Lenmeldy as the first gene therapy in the U.S. for kids with certain types of metachromatic leukodystrophy (MLD).

Cutting, meet edge: J&J MedTech taps Nvidia for surgery AI partnership

By Conor Hale

Johnson & Johnson MedTech has tapped Nvidia to help deliver real-time analyses of surgical data with AI models that can be deployed on-site using edge computing.

Parexel CEO Jamie Macdonald to hand reins over to growth officer

By Helen Floersh

Parexel CEO Jamie Macdonald will retire from his post effective May 15. He will be succeeded by Peyton Howell, who currently serves as chief operating and growth officer, and will remain on the board of directors through the end of the year

#FierceMadness: Grab a bracket and vote for the most overused buzzword in healthcare!

By Paige Minemyer

The NCAA basketball tournament gets underway today, and the Fierce Healthcare team is gearing up yet again for our annual #FierceMadness competition.

Fierce podcasts

Don’t miss an episode

'The Top Line': Inclusivity in psoriasis trials with Takeda

In this episode of 'The Top Line,' Fierce Biotech Senior Editor Annalee Armstrong interviews Karen Correa, Ph.D., from Takeda, discussing the crucial need for pharmaceutical companies to prioritize diversity in clinical trials.

'Podnosis': A deep dive into health plan and health system earnings

'The Top Line': Fierce Medtech's Fierce 15

Resources

Whitepaper

Pediatric Clinical Trials: Considerations for Enrollment and Retention

Explore the nuanced approaches necessary for successful pediatric drug development.

CNS Market Outlook, 2024

This paper assesses the current state of the broad CNS market, reviewing key expectations for 2024. It addresses Alzheimer’s disease, biomarkers, and advances in psychiatry in detail. It also provides a high-level look at the pain market and the evolving regulatory environment.

Presented by Blue Matter, strategic consultants in the life sciences